Faeth Therapeutics Inc.

FTH | NASDAQ

Price Alert Chart Builder DCF Calculator

$18.69

-$0.06 (-0.32%)

At close: Oct 30, 2026, 4:00 PM ET

$18.32

-$0.37 (-1.98%)

After-hours: Oct 30, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $481.8M

Enterprise Value $295.96M

Beta -0.29

Average Volume 336.56K

Shares Outstanding (Diluted) 5.64M

Shares Change YoY 347.57%

Institutional Ownership N/A

Exchange NASDAQ

ISIN US81728A2078

Price Performance

Price Change 1M -37.2%

Price Change 3M -31.4%

Price Change 6M -30.7%

Price Change YTD 75.2%

Price Change 1Y 103.8%

Price Change 3Y 31.4%

Price Change 5Y -89.3%

1M CAGR (ann.) -45.8%

1Y CAGR (ann.) 99.3%

5Y CAGR (ann.) -33.3%

All-Time CAGR -40.8%

Valuation

PE Ratio -0.13

Forward PE N/A

PEG Ratio 0.00

Forward PEG 0.01

PS Ratio -99.32

Forward PS N/A

PB Ratio 2.79

P/FCF Ratio -14.23

P/Adj. FCF Ratio -9.30

P/OCF Ratio -3.12

EV/Sales -61.01

EV/EBIT -1.51

EV/EBITDA -1.51

EV/FCF -8.74

Earnings Yield -757.9%

FCF Yield -7.0%

Adj. FCF Yield -10.8%

Financial Health

Net Cash $186.44M

Total Debt $592K

Cash & Short-Term Investments $186.44M

Total Assets $189.31M

Current Ratio 19.69

Quick Ratio 19.69

Debt / Equity Ratio 0.00

Debt / EBITDA -0.00

Debt / FCF -0.02

OCF / Debt -57.19

Interest Coverage -22,091.11

Altman Z-Score 11.91

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 2740.8%

Operating Profit Margin 4098.5%

EBITDA Margin 4028.0%

Net Profit Margin 4030.7%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue -369.6%

SBC Impact (per share) -52.9%

Returns

Return on Assets -103.3%

Return on Equity -192.8%

Return on Invested Capital -110.3%

Return on Capital Employed -110.6%

Return on Tangible Assets -103.3%

Historical Growth (CAGR)

Revenue CAGR 3Y -150.0%

Revenue CAGR 5Y -100.0%

Revenue CAGR 10Y N/A

EPS CAGR 3Y -95.0%

EPS CAGR 5Y -45.3%

EPS CAGR 10Y N/A

FCF CAGR 3Y -17.2%

FCF CAGR 5Y 6.4%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 2

EPS Growth Next 3Y 32.5%

Revenue Growth Next 3Y 81.3%

Earnings Date Nov 13, 2026

EPS Estimate (next Q) -$0.71

EPS Growth Est (next Q) -80.3%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $58.50

Price Target Upside 213.0%

Cash Flow

Operating Cash Flow $-33.86M

Free Cash Flow $-33.86M

Adj. Free Cash Flow $-51.79M

FCF Per Share -$6.00

OCF Per Share -$6.00

OCF/S Ratio 697.9%

Income Statement

Revenue $-4.85M

Gross Profit $-132.96M

Operating Income $-198.82M

EBITDA $-195.4M

Net Income $-195.53M

EPS (Diluted) -$141.65

Revenue / Employee $-167.28K

Profit / Employee $-6.74M

Employees 29